Previous Close | 4.5300 |
Open | 4.4200 |
Bid | 0.0000 x 4000 |
Ask | 0.0000 x 1800 |
Day's Range | 4.2200 - 4.7900 |
52 Week Range | 4.0000 - 14.7300 |
Volume | |
Avg. Volume | 2,404,091 |
Market Cap | 353.562M |
Beta (5Y Monthly) | 0.04 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.7600 |
Earnings Date | May 02, 2022 - May 06, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.50 |
The company's second-quarter performance had some highlights, but investors might have been concerned about full-year guidance.
For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk...
Today, I'm joined by Richard Paulson, president and chief executive officer; Sohanya Cheng, chief commercial officer; Dr. Reshma Rangwala, chief medical officer; and Mr. Mike Mason, chief financial officer. Earlier this morning, we issued a press release detailing Karyopharm's financial results for the second quarter 2022.